Member Type: Emerging Biotech/Pharmaceutical Companies
At Ignyta, they fight cancer - a formidable opponent that manifests as thousands of different molecularly defined diseases and takes away millions of lives globally, every year. In this fight, their vision is not just to shrink tumors but to eradicate residual disease - the source of cancer relapse and recurrence - in precisely defined patient populations by 2030. They work to achieve this vision by pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Their Rx efforts are focused on discovering, in-licensing or acquiring, then developing and commercializing, molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Their Dx efforts aim to pair these product candidates with biomarker-based companion diagnostics that are designed to precisely identify, at the molecular level, the patients who are most likely to benefit from the therapies they develop.